<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>JAK2 V617F mutation recently was identified as a pathogenic factor in typical <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mpath ids='MPATH_512'>myeloproliferative diseases</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMPD</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Some forms of <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) show a significant overlap with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMPD</z:e> (classified as <z:e sem="disease" ids="C1301355" disease_type="Neoplastic Process" abbrv="">MDS/MPD</z:e>), but the diagnostic assignment may be challenging </plain></SENT>
<SENT sid="2" pm="."><plain>We studied blood or bone marrow from 270 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, <z:e sem="disease" ids="C1301355" disease_type="Neoplastic Process" abbrv="">MDS/MPD</z:e>, and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMPD</z:e> for the presence of JAK2 V617F mutation using polymerase chain reaction, sequencing, and melting curve analysis </plain></SENT>
<SENT sid="3" pm="."><plain>The detection rate of JAK2 V617F mutants for <z:hpo ids='HP_0001901'>polycythemia</z:hpo> vera, <z:hpo ids='HP_0011010'>chronic</z:hpo> idiopathic <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo>, and <z:e sem="disease" ids="C0040028" disease_type="Disease or Syndrome" abbrv="">essential thrombocythemia</z:e> (n = 103) was similar to the previously reported results </plain></SENT>
<SENT sid="4" pm="."><plain>In typical forms of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (n = 89) JAK2 V617F mutation was very rare (n = 2) </plain></SENT>
<SENT sid="5" pm="."><plain>However, a higher prevalence of this mutation was found in patients with <z:e sem="disease" ids="C1328061" disease_type="Neoplastic Process" abbrv="">MDS/MPD-U</z:e> (9 of 35) </plain></SENT>
<SENT sid="6" pm="."><plain>Within this group, most of the patients harboring JAK2 V617F mutation showed features consistent with the provisional <z:e sem="disease" ids="C1328061" disease_type="Neoplastic Process" abbrv="">MDS/MPD-U</z:e> entity <z:hpo ids='HP_0004828'>refractory anemia with ringed sideroblasts</z:hpo> and <z:hpo ids='HP_0001894'>thrombocytosis</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>-T) </plain></SENT>
<SENT sid="7" pm="."><plain>Among 9 RARS-T patients, 6 showed the presence of JAK2 V617F mutation, and in 1 patient without mutation, aberrant, positive phospho-STAT5 staining was seen that is typically present in association with JAK2 V617F mutation </plain></SENT>
<SENT sid="8" pm="."><plain>In summary, we found that <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>-T reveals a high frequency of JAK2 V617F mutation and likely constitutes another JAK2 mutation-associated form of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMPD</z:e> </plain></SENT>
</text></document>